SEC Form 4 · accession 0001610717-26-000242
10x Genomics, Inc. · TXG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shehnaaz Suliman
Director
Period of report
Jun 16, 2026
Accepted (ET)
Jun 18, 2026 · 4:08 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001770787
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF2 | Jun 16, 2026 | S | 5,359 | $32.589 | D | 32,086 | D | |
| Class A Common StockF3 | Jun 16, 2026 | S | 364 | $33.2738 | D | 31,722 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026.
- F2This transaction was executed in multiple trades at prices ranging from $32.03 to $33.02, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3This transaction was executed in multiple trades at prices ranging from $33.03 to $33.49, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.